BusinessMedical Innovations

Push Accelerates for Artificial Pancreas for Type 1 Diabetes

1 Mins read

By recently releasing guidelines for premarket approval and investigation device exemption of “artificial pancreas” devices, the FDA set the stage for approval of these systems in the management of type 1 diabetes. 

By recently releasing guidelines for premarket approval and investigation device exemption of “artificial pancreas” devices, the FDA set the stage for approval of these systems in the management of type 1 diabetes. 

The term “artificial pancreas” derives from the potential ability of devices to artificially replace the functions of healthy pancreases in regulating blood glucose, a function that has been lost in type 1 diabetics.  The components of artificial pancreases are principally an insulin pump, a continuous blood glucose monitor and the necessary algorithm or controls to enable feedback from the glucose monitor to regulate insulin infusion rates.  Insulin pumps have been on the market for a number of years and sales of approved versions of continuous blood glucose monitors have begun to escalate.  Systems combining both pumps and monitors are also on the market but currently not in what is known as “closed loop” systems in which glucose levels are regulated by varying insulin infusion rates directly, without patient intervention.  Given the variables impacting blood glucose levels and the potential for inadequately regulated insulin infusion to result in dangerous hypoglycemia, the technology of safely closing the loop of glucose/insulin regulation has been a challenge, at least in terms of meeting FDA approval.

A number of companies are active in the development of closed loop, “artificial pancreas” systems including J&J/Animas Systems, DexCom, Medtronic and others. 


Products, technologies and companies in the field of diabetes are the subject of the MedMarket Diligence report $D510.

     

Avatar
183 posts

About author
I serve the interests of medical technology company decision-makers, venture-capitalists, and others with interests in medtech producing worldwide analyses of medical technology markets for my audience of mostly medical technology companies (but also rapidly growing audience of biotech, VC, and other healthcare decision-makers). I have a small staff and go to my industry insiders (or find new ones as needed) to produce detailed, reality-grounded analyses of current and potential markets and opportunities. I am principally interested in those core clinical applications served by medical devices, which are expanding to include biomaterials, drug-device hybrids and other non-device technologies either competing head-on with devices or being integrated with devices in product development. The effort and pain of making every analysis global in scope is rewarded by my audience's loyalty, since in the vast majority of cases they too have global scope in their businesses. Specialties: Business analysis through syndicated reports, and select custom engagements, on medical technology applications and markets in general/abdominal/thoracic surgery, interventional cardiology, cardiothoracic surgery, patient monitoring/management, wound management, cell therapy, tissue engineering, gene therapy, nanotechnology, and others.
Articles
Related posts
Business

Building Your HGH Levels for Better Health and Stronger Muscles

7 Mins read
Over the years, people have tried countless methods to grow muscles and achieve their ultimate physical goals. Using different performance enhancers and…
Business

6 Critical Healthcare Marketing Tactics to Win Over New Patients

3 Mins read
Finding clients for a medical practice is not easy. It is even harder in 2020 than it was years ago. Changing customer…
Business

How To Cater For Different Learning Styles When Training Employees

2 Mins read
Diversity in the workplace has become a common thing. People from all walks of life are coming together to collaborate and deliver…